High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses
Leukemia, 05/09/2012
Clinical Article
Metzelder SK et al. – Sorafenib monotherapy has significant activity in FLT3–ITD acute myeloid leukemia (AML) and may synergize with allogeneic immune effects to induce durable remissions.



